Back to Results

In8bio Inc (INAB)

IN8bio, Inc. is a NASDAQ-listed common stock company focused on biotechnology and healthcare. The company is a clinical-stage biopharmaceutical developer working on gamma-delta T cell-based product candidates for cancer and autoimmune diseases. Its pipeline includes INB-400, being studied in Phase 2 for newly diagnosed glioblastoma, as well as INB-200 and INB-100, both in early-stage clinical development for glioblastoma and hematologic malignancies, respectively. Additional programs include INB-619, INB-300, INB-500, and INB-600, which are being advanced across oncology and autoimmune disease research. Founded in 2016, the company is headquartered in New York, New York, and was previously known as Incysus Therapeutics, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-INAB
$1.27
52.6% Upside
Bargain
$7
743.4% Upside
Bargain
Fair
0.0%
0.4x
8.182 M
-7.597 M
21.0%
72.9%
-14.7
78.2%
Valuation • Fair Value

In8bio Inc (NASDAQ-INAB) Fair Value by Valuation Model

Review the available estimates for In8bio Inc (NASDAQ-INAB), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.27

Estimated upside of 52.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.27

Comparable-company valuation reference.

Analyst Price Target

$7

Analysts imply upside of 743.4%.

How to read these valuation models

Use the 4 available valuation references for In8bio Inc (NASDAQ-INAB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for In8bio Inc (NASDAQ-INAB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-17.797 M

Current operating profitability reference.

EBITDA Forecast

-26 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review In8bio Inc (NASDAQ-INAB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for In8bio Inc (NASDAQ-INAB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-14.7

Lower score that deserves closer risk review.

FCF / Net Income

78.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for In8bio Inc (NASDAQ-INAB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for In8bio Inc (NASDAQ-INAB)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for In8bio Inc (NASDAQ-INAB). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

In8bio Inc (NASDAQ-INAB) Stock Forecast & Technical Outlook

Review In8bio Inc (NASDAQ-INAB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for In8bio Inc (NASDAQ-INAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for In8bio Inc (NASDAQ-INAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for In8bio Inc (NASDAQ-INAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for In8bio Inc (NASDAQ-INAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for In8bio Inc (NASDAQ-INAB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for In8bio Inc (NASDAQ-INAB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, In8bio Inc (NASDAQ-INAB) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

In8bio Inc (NASDAQ-INAB) Stock FAQ

Data-supported answers about In8bio Inc (NASDAQ-INAB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.27
Estimated upside 52.6%
Valuation Rating
Undervalued
Estimated upside of 52.6%
Analyst Target
$7
Implied upside 743.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for In8bio Inc (NASDAQ-INAB) is $1.27. This implies an estimated upside of 52.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 52.6% versus the current market price.

The available analyst price target for In8bio Inc (NASDAQ-INAB) is $7. The analyst target implies estimated upside of 743.4%.

The current financial health read for In8bio Inc (NASDAQ-INAB) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for In8bio Inc (NASDAQ-INAB).

The current market capitalization listed for In8bio Inc is 8.182 M.

The current enterprise value listed for In8bio Inc is -7.597 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for In8bio Inc is NASDAQ-INAB, and the stock is listed on NASDAQ.

In8bio Inc (NASDAQ-INAB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for In8bio Inc is 21.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for In8bio Inc is 72.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B